FACTS

The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center is one of the top cancer treatment and research centers in the country. In 2016, the National Cancer Institute elevated UMGCCC to its designation as a comprehensive cancer center — one of just less than 75 in the nation — a designation renewed in 2021. As part of the University of Maryland Medical System, we offer innovative approaches to diagnosing and treating all types of cancer, conduct cutting-edge research to bring the latest advances in cancer treatment directly to our patients, and provide cancer screening and patient education services. The UMGCCC is at the forefront of successful efforts which are driving down the impact of cancer in Maryland.

OUTSTANDING PATIENT CARE & SCIENTIFIC EXCELLENCE

A team approach to care, in which specialists from all cancer disciplines work together to develop an individualized treatment plan for each patient.

Minimally invasive treatment options, including stereotactic body radiation therapy, robot-assisted surgery and the newest, targeted drug therapies.

Innovative clinical trials offering patients promising new therapies, often years before they are available commercially.

Patient-focused treatment environment featuring private rooms for all inpatients, the Stoler Pavilion for outpatient care and a dedicated pharmacy and infusion center.

An active translational research program, making advances in developing cancer vaccines, new technologies, novel cancer-fighting agents and promising combination therapies.

Top-rated nursing staff specially trained in cancer care and consistently rated as outstanding in patient satisfaction surveys. Accredited with a four-year Magnet® designation from the American Nurses Credentialing Center (ANCC), nursing staff of the University of Maryland Medical Center are also among the best in the nation.

Support services, including social work, patient navigators, genetic and nutrition counseling, palliative care and a specialized image renewal center offering wigs, skin care and other services.

Education, outreach and free cancer screenings for underserved individuals through the Baltimore City Cancer Program. Find out more at umm.edu/hope or by calling 410-328-HOPE.

The University of Maryland Cancer Network allows Maryland residents to benefit from specialized cancer expertise and clinical trials close to home.

The building of the nearly 200,000 square foot Roslyn and Leonard Stoler Center for Advanced Medicine is underway, and will be the new home of the UMGCCC. The facility will roughly double the amount of space of the current cancer center and house state-of-the art outpatient clinics and treatment areas, and expanded inpatient clinics beds with innovative options for patients, families and visitors.

QUICK NUMBERS

59,000+ Outpatient Visits
1,100+ Inpatient Admissions
3,000+ New Patients Annually
484 Clinical Trials
280 Physicians and Researchers
$122 Million Annual Research Funding

CANCER TREATMENT SPECIALTIES

Brain Cancer
Breast Evaluation and Treatment
Cardio-Oncology
Endocrine Malignancies
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Head and Neck Cancer
Hematologic Malignancies
Neuro-Oncology
Ocular Oncology
Pediatric Oncology
Skin Cancer
Transplant and Cell Therapy (Bone Marrow and CAR-T)
Thoracic/Lung Cancer

umgccc.org
OUR NATIONAL PROFILE

In 2016, UMGCCC became a National Cancer Institute (NCI)-Designated Comprehensive Cancer Center, a distinction shared by just 71 centers across the US. Of these centers, 53 are Comprehensive Cancer Centers like the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCC).

Cancer research funding at UMGCCC has grown dramatically since 2002—from $19.4 million to $122 million—and continues to drive scientific discovery by our cancer experts, all of whom are faculty of the UM School of Medicine.

UMGCC is a leader in addressing cancer disparities, with research focused on improving access to care and treatment outcomes for minorities, who represent 53 percent of the patients in our clinical trials, compared to 16 percent nationally.

The Maryland Proton Treatment Center is a state-of-the-art facility that provides proton therapy, a highly advanced and precise form of radiation for adult and pediatric patients that increases the radiation dose to tumors while decreasing the dose to healthy, surrounding tissue.

UMGCC is a national leader in developing immunotherapy approaches that train a patient’s own immune system to fight cancer. More than two dozen clinical trials utilize immunotherapy and are supported by UMGCCC’s Fannie Angelos GMP (Good Manufacturing Practice) Lab that permits cancer center investigators to genetically engineer patients’ T cells to recognize and attack their cancers.

UMGCC was the first cancer center in the Baltimore/Washington area to offer CAR-T cell therapy for aggressive B cell lymphomas. We now offer CAR-T therapy for several types of B cell lymphoma, leukemia and myeloma. UMGCCC has the most advanced cell therapy research and production laboratory in the region which is developing the next generation of cellular therapies for blood cancers.

The GammaPod is a stereotactic breast radiation therapy system all designed specifically for breast cancer treatment. This FDA-cleared technology was invented at the University of Maryland School of Medicine and delivers partial breast radiation therapy in a targeted manner, and can significantly shorten treatment time with minimal side effects.

Galeteron, a drug invented at UMGCCC by investigators Dr. Angela Brodie and Dr. Vincent Njar, has shown significant activity against advanced prostate cancer. More recent studies are promising in laboratory models of pancreatic cancer. A clinical trial for this difficult disease is underway.

Dr. Graeme Woodworth received FDA clearance to become the first in the US to open the blood-brain barrier, which protects the brain from toxins but makes it difficult to treat brain cancer with chemotherapy. By using focused ultrasound and microbubbles, we can disrupt the barrier and inject an agent directly into a brain tumor.

Led by Dr. Stuart Martin, UM researchers developed a novel TetherChip device to test for the presence of thin membrane protrusions called “microtentacles” on breast cancer cells, which can help predict whether a tumor is likely to spread. Microtentacles play a key role in helping cancer cells spread from the original tumor and reattach themselves in distant organs, identifying and targeting of which could lead to important new advances in cancer treatment.

During FY2023, the Cigarette Restitution Fund, including Governor Hogan’s supplemental Cancer Moonshot, supported 76 existing positions and created another 21 full-time jobs within UMGCCC.